Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Kaposi sarcoma, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Access to effective chemotherapy and ART-linked cancer care in sub-Saharan Africa.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
KS in people with suppressed HIV and normal CD4 counts (unexplained).
No antiviral therapy targets latent KSHV.
Endemic childhood KS in Africa still lacks access to the chemotherapy that treats it.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Kaposi sarcoma (AIDS-related after ART failure; HIV-negative)
ART plus paclitaxel where available (ACTG A5263); bleomycin-vincristine otherwise; task-shifted oncology nursing models.
Week-48 progression-free survival 50 percent with paclitaxel against 20 percent with oral etoposide, and 64 percent against 44 percent with bleomycin plus vincristine; both investigational arms were inferior and closed early.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.